Fast Facts about the Johnson & Johnson COVID-19 Vaccine and the CDC’s Preferential Recommendation for mRNA COVID-19 Vaccines

CDC has recently made changes to its recommendation of the Johnson and Johnson (J&J) Janssen COVID-19 vaccine. As of December 16, 2021, CDC now expresses a clinical preference for individuals to receive an mRNA COVID-19 vaccine (Moderna and Pfizer-BioNTech) over the J&J vaccine. mRNA vaccines are now preferred over the Janssen COVID-19 vaccine for the prevention of COVID-19 for those 18 years of age and over.

This change from a full recommendation to a ‘preferential recommendation’ can be confusing for providers and patients. Below we offer some answers to common questions about the change.

**What is a preferential recommendation?**
The Advisory Committee on Immunization Practices (ACIP) can recommend some vaccines over others due to their effectiveness, safety, and availability—this is called a preferential recommendation.

**Why are mRNA vaccines preferred over the J&J vaccine?**
The CDC’s preference to use mRNA vaccines comes after a review of new evidence, which suggests that rates of a rare blood clotting disorder (thrombosis with thrombocytopenia syndrome or TTS) linked to the J&J vaccine are higher than previously estimated.

**Is the J&J vaccine still authorized by the FDA?**
Yes, the J&J COVID-19 vaccine still maintains its Emergency Use Authorization (EUA) to prevent COVID-19 in individuals 18 years of age and older. The EUA has been updated with the risk data mentioned below, but the preferential recommendation is not mentioned in the EUA because such a recommendation is the domain of the CDC and not the FDA.

**Does CDC still recommend the J&J vaccine?**
To some extent, yes. While the use of mRNA COVID-19 vaccines is preferred over the J&J COVID-19 vaccine for all vaccine-eligible persons, ACIP and CDC agree that receiving any vaccine is better than being unvaccinated. CDC continues to recommend the J&J COVID-19 vaccines in some situations.

**Under what circumstances may a J&J vaccine be administered?**
CDC identifies **three situations** under which the J&J COVID-19 vaccine may be administered:

- When there is a **contraindication** to mRNA COVID-19 vaccines (e.g., severe allergic reaction after a previous dose or to a component of an mRNA COVID-19 vaccine)
- When a person would otherwise remain unvaccinated for COVID-19 due to **limited access** to mRNA COVID-19 vaccines
- When a person **wants** to receive the Janssen COVID-19 vaccine **despite** the safety concerns

**How long after receiving the J&J COVID-19 vaccine might TTS occur?**
Reports of TTS following the use of the J&J COVID-19 Vaccine indicate onset of symptoms began approximately 1 to 2 weeks after vaccination. It is recommended that for **3 weeks** after receiving this vaccine, patients should be aware of possible symptoms of a blood clot with low platelets and seek medical care immediately if these symptoms occur.

Disclaimer: This project was funded in whole by a cooperative agreement with the Centers for Disease Control and Prevention grant number NU50CK000588. The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this resource center do not necessarily represent the policy of CDC or HHS and should not be considered an endorsement by the Federal Government.
The overall reporting rate of TTS following J&J vaccinations is ~3.8 cases per million doses.

Providers and vaccinators should encourage their patients to take a COVID-19 mRNA vaccine if they are readily available, but if a patient shows interest in the J&J vaccine and is opposed to the mRNA vaccines (for whatever reason, be it a preference for viral vector vaccines, contraindications, or concerns about the safety profile of mRNA vaccines regarding myocarditis), then they can still receive the J&J COVID-19 vaccine.

Given this safety profile and the abundance of mRNA COVID-19 vaccines available in the U.S., the CDC prefers mRNA vaccines over the J&J COVID-19 vaccine. This updated CDC recommendation follows similar recommendations from other countries, including Canada and the United Kingdom.

Should patients receive the J&J vaccine as a booster dose?

CDC’s preferential recommendation applies to the use of the J&J vaccine as a primary dose and a booster shot. When possible, mRNA COVID-19 vaccines are preferred.

It is contraindicated to administer the J&J vaccine to persons with a history of TTS following receipt of this vaccine or any other adenovirus vector-based COVID-19 vaccines. These people should receive a dose of an mRNA COVID-19 vaccine as a booster at least 2 months (8 weeks) following their dose of the J&J vaccine and after their clinical condition has stabilized.

Prior to booster vaccination, a conversation between the patient and their clinical team, including a hematologist or other specialists, may assist with decisions about using an mRNA COVID-19 vaccine as a booster and the timing of the booster vaccination.

What do I do if a patient asks for the J&J vaccine?

Providers and vaccinators should encourage their patients to take a COVID-19 mRNA vaccine if they are readily available, but if a patient shows interest in the J&J vaccine and is opposed to the mRNA vaccines (for whatever reason, be it a preference for viral vector vaccines, contraindications, or concerns about the safety profile of mRNA vaccines regarding myocarditis), then they can still receive the J&J COVID-19 vaccine.

Before administering the J&J vaccine, providers should ensure that the patient knows the risks associated with the J&J vaccine. They should check that the patient has read the fact sheet fully and understands all the risks involved. They need to discuss the possibility TTS after receipt of the J&J COVID-19 vaccine and explain that there are other COVID-19 vaccine options available for which this specific risk has not been seen.

If the patient gives full informed consent, then they can still receive the J&J vaccine.

After administering the J&J vaccine, providers should encourage their patients to be attentive to symptoms of TTS for the next 3 weeks.

What are the symptoms of TTS?

The primary symptoms of TTS following vaccination include:

- Shortness of breath
- Chest pain
- Leg swelling
- Persistent abdominal pain
- Severe or persistent headaches or blurred vision
- Easy bruising or tiny blood spots under the skin beyond the injection site
- Severe or persistent headaches or blurred vision
- Easy bruising or tiny blood spots under the skin beyond the injection site
- Shortness of breath
- Chest pain
- Leg swelling
- Persistent abdominal pain
- Severe or persistent headaches or blurred vision
- Easy bruising or tiny blood spots under the skin beyond the injection site

How common are cases of TTS following administration of the J&J vaccine?

| The overall reporting rate of TTS following J&J vaccinations is | For women between 30-49 years of age, this rate increases to |
| ~3.8 cases per million doses | ~10 cases per million doses |

15% of all these TTS cases have been fatal.

For women between 30-49 years of age, this rate increases to 15% of all these TTS cases have been fatal.

What do I do if a patient asks for the J&J vaccine?

Providers and vaccinators should encourage their patients to take a COVID-19 mRNA vaccine if they are readily available, but if a patient shows interest in the J&J vaccine and is opposed to the mRNA vaccines (for whatever reason, be it a preference for viral vector vaccines, contraindications, or concerns about the safety profile of mRNA vaccines regarding myocarditis), then they can still receive the J&J COVID-19 vaccine.

Before administering the J&J vaccine, providers should ensure that the patient knows the risks associated with the J&J vaccine. They should check that the patient has read the fact sheet fully and understands all the risks involved. They need to discuss the possibility TTS after receipt of the J&J COVID-19 vaccine and explain that there are other COVID-19 vaccine options available for which this specific risk has not been seen.

If the patient gives full informed consent, then they can still receive the J&J vaccine.

After administering the J&J vaccine, providers should encourage their patients to be attentive to symptoms of TTS for the next 3 weeks.